In summary, as our understanding of the NLRP3 inflammasome in LN continues to deepen, it will pave the way for novel, mechanism-based therapies, not only for LN but also for a broad spectrum of NLRP3-driven autoimmune and inflammatory diseases. This evidence concerns the gene NLRP3 and lobular neoplasia.